SpringWorks Therapeutics, Inc.
SWTXDelisted Jul 1, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001773427
SpringWorks Therapeutics, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.65B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in SpringWorks Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
SWTX is no longer listed, and 13F filings after Q2 2025 list far fewer holders. See Q2 2025
- Institutional holders
- 3
- −217 vs. Q2 2025
- Shares held
- 40.1K
- −75.8M (−99.9%) vs. Q2 2025
- Total value
- $2.16M
- −$3.56B (−99.9%) vs. Q2 2025
- New holders
- 0
- 0 more added
- Sold out
- 217
- 2 more reduced
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SWTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $47 |
| Q1 2026 | 1 | $47 |
| Q4 2025 | 2 | $2.18M |
| Q3 2025 | 3 | $2.16M |
| Q2 2025 | 223 | $3.65B |
| Q1 2025 | 306 | $3.29B |
| Q4 2024 | 216 | $2.92B |
| Q3 2024 | 226 | $2.59B |
| Q2 2024 | 209 | $2.91B |
| Q1 2024 | 217 | $3.85B |
| Q4 2023 | 180 | $2.75B |
| Q3 2023 | 147 | $1.58B |
| Q2 2023 | 142 | $1.82B |
| Q1 2023 | 149 | $1.70B |
| Q4 2022 | 137 | $1.73B |
| Q3 2022 | 148 | $1.80B |
| Q2 2022 | 144 | $1.36B |
| Q1 2022 | 136 | $2.79B |
| Q4 2021 | 144 | $2.82B |
| Q3 2021 | 142 | $2.86B |
| Q2 2021 | 135 | $3.69B |
| Q1 2021 | 137 | $3.23B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding SpringWorks Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −116−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −89−100.0% | Sold out |
| Highline Wealth Partners LLC | 0 | $0 | 0.00% | −62−100.0% | Sold out |
| Bayforest Capital Ltd | 0 | $0 | 0.00% | −57−100.0% | Sold out |
| Parkside Financial Bank & Trust | 0 | $0 | 0.00% | −54−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −43−100.0% | Sold out |
| Wolff Wiese Magana LLC | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Global Retirement Partners, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −31−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| Bell Investment Advisors, Inc | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| Massmutual Trust Co FSB | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| American National Bank | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |
| First Horizon Advisors, Inc. | – | – | – | – | Not filed |